The food noise comes back, and for many, this is the hardest part
Topline data from the Phase 3, open-label EMBER-3 clinical trial among patients with estrogen receptor 1 (ESR1) gene mutations who received prior endocrine therapy revealed a median progression-free survival (PFS) of 5.5 months with imlunestrant compared to 3.8 months with placebo (hazard ratio [HR], 0.62
Call our office today by clicking here to discuss your options and ensure continued access to the treatment that works for you
Through its multifaceted mechanisms of action, including improved glycemic control, weight loss, anti-inflammatory effects, blood pressure regulation, lipid profile improvements, and enhancement of endothelial function, semaglutide provides a comprehensive approach to cardiovascular risk reduction